

Literatur für onkologie heute 9/2020

SCHWERPUNKT: IMMUNONKOLOGIE, KOPF-HALS-TUMOREN

Systemische Erstlinien- und Sequenztherapie des metastasierten Urothelkarzinoms (S. 26–29)

G. Niegisch

1. Sternberg CN et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. *J Clin Oncol* 2001; 19(10): 2638–2646
2. von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000; 18(17): 3068–77
3. Galsky MD et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. *J Clin Oncol* 2011; 29(17): 2432–2438
4. Dash A et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. *Cancer* 2006; 107(3): 506–513
5. Balducci L and Yates J. General guidelines for the management of older patients with cancer. *Oncology (Williston Park)* 2000; 14(11A): 221–227
6. Niegisch G et al. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. *J Cancer* 2018; 9(8): 1337–1348
7. De Santis, M., et al., Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. *J Clin Oncol* 2012; 30(2): 191–9
8. Grimm, M.O., [Immunooncology in Urologic Cancers: Current Status]. *Aktuelle Urol* 2016; 47(5): 374–377
9. Bidnur, S., R. Savdie, and P.C. Black, Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. *Bladder Cancer* 2016; 2(1): 15–25
10. Balar, A.V., et al., Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet* 2017; 389(10064): 67–76
11. Balar, A.V., et al., First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. *Lancet Oncol* 2017; 18(11): 1483–1492
12. Galsky, M.D., et al., Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2020; 395(10236): 1547–1557
13. Powles et al. LBA 1, ASCO 2020
14. Bellmunt, J., et al., Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *N Engl J Med* 2017; 376(11): 1015–1026
15. Powles, T., et al., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2018; 391(10122): 748–757

16. Rosenberg, J.E., et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387(10031): 1909–1920
17. Sharma, P., et al., Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2017; 18(3): 312–322
18. Bellmunt, J., et al., Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J Clin Oncol* 2009; 27(27): 4454–4461
19. Sweeney, C.J., et al., A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. *Cancer* 1999; 86(3): 514–518
20. Soga, N., et al., Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. *Int J Urol* 2007; 14(9): 828–832
21. Lin, C.C., et al., Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. *Anticancer Drugs* 2007; 18(4): 487–491
22. Krege, S., et al., Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. *J Urol* 2001; 165(1): 67–71
23. Albers, P., et al., Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. *Ann Oncol* 2011; 22(2): 288–294
24. Sternberg, C.N., et al., Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. *Cancer* 2001; 92(12): 2993–2998
25. Fechner, G., et al., Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). *Int J Clin Pract* 2006; 60(1): 27–31
26. Kanai, K., et al., Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. *Int J Clin Oncol* 2008; 13(6): 510–514
27. Suyama, T., et al., Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. *Jpn J Clin Oncol* 2009; 39(4): 244–250
28. Locke, J.A., et al., Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. *Clin Genitourin Cancer* 2016; 14(4): 331–340
29. Necchi, A., et al., Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. *Clin Genitourin Cancer* 2015; 13(2): 178–184

Aktuelle Therapieaspekte des Plattenepithelkarzinoms im Kopf-Hals-Bereich (S. 38–44)

J. Doescher, M. Brand und T. K. Hoffmann

1. Li RJ, Richmon JD. Transoral Endoscopic Surgery: New Surgical Techniques for Oropharyngeal Cancer. *Otolaryngol Clin North Am* 2012; 45: 823–844
2. Hagemann J, Roesner J, Helling S, Jacobi C, Doescher J, Engelbarts M, et al. Long-term Outcome for Open and Endoscopically Resected Sinonasal Tumors. *Otolaryngol Head Neck Surg* 2018: 194599818815881

3. Arens C. Transoral treatment strategies for head and neck tumors. *GMS Curr Top Otorhinolaryngol Head Neck Surg* 2012; 11: Doc05
4. Kishimoto Y, Tateya I, Funakoshi M, Miyamoto S ichi, Muto M, Omori K. Endoscopic laryngopharyngeal surgery for hypopharyngeal lesions. *Oral Oncol* 2020;106: 104655
5. Schuler PJ. Robotische Chirurgie – operiert der Roboter? *Laryngorhinootologie* 2018; 97: S231–278
6. Hinni ML, Zarka MA, Hoxworth JM. Margin mapping in transoral surgery for head and neck cancer. *Laryngoscope* 2013; 123: 1190–1198
7. Thomas Robbins K, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, et al. Neck dissection classification update: Revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. *Arch Otolaryngol - Head Neck Surg* 2002; 128: 751–758
8. Vahl JM, Hoffmann TK. Neck-Dissection – Die operative Behandlung der zervikalen Lymphabflusswege. *HNO* 2019; 67: 61–76.
9. Govers TM, Hannink G, Merckx MAW, Takes RP, Rovers MM. Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: A diagnostic meta-analysis. *Oral Oncol* 2013; 49: 726–732
10. Garrel R, Perriard F, Favier V, Richard F, Daures JP, De Boutray M. Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. *J Clin Oncol* 2020; 38: 6501
11. Knopf A, Jacob S, Bier H, Scherer EQ. Bilateral versus ipsilateral neck dissection in oral and oropharyngeal cancer with contralateral cN0 neck. *Eur Arch Oto-Rhino-Laryngology* 2020
12. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). *Head Neck* 2005; 27: 843–850
13. Ogol'tsova ES, Paches AI, Matiakin EG, Dvořin V V, Fedotenko SP, Alferov VS, et al. [Comparative evaluation of the effectiveness of radiotherapy, surgery and combined treatment of stage I-II laryngeal cancer (T1-2NoMo) based on the data of a cooperative randomized study]. *Vestn Otorinolaringol* 1990: 3–7
14. Stelmes J-J, Gregoire V, Poorten V Vander, Golusiński W, Szewczyk M, Jones T, et al. Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” Trial. *Front Oncol* 2019; 9: 999
15. Busch C-J, Laban S, Wittekindt C, Stromberger C, Tribius S, Betz CS, et al. Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC). *J Clin Oncol* 2019; 37: TPS6093–TPS6093
16. Allen CT, Judd NP, Bui JD, Uppaluri R. The clinical implications of antitumor immunity in head and neck cancer. *Laryngoscope* 2012; 122: 144–157
17. Hoffmann TK, Ballo H, Braunstein S, Van Lierop A, Wagenmann M, Bier H. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. *Oral Oncol* 2001; 37: 50–56
18. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2006; 354: 567–78
19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol* 2010; 11: 21–28

20. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *J Clin Oncol* 2014; 32: 2940–2950
21. Chao KSC, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. *Radiother Oncol* 2001; 61: 275–280
22. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain? *Cancer Treat Rev* 2011; 37: 511–519
23. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final results of local-regional control and late toxicity of rtog 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer. *Int J Radiat Oncol Biol Phys* 2014; 89: 13–20
24. Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. *Pract Radiat Oncol* 2017; 7: 246–253
25. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2004; 350: 1937-1944+2019
26. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010; 363: 24–35
27. Cramer JD, Ferris RL, Kim S, Duvvuri U. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment. *Oral Oncol* 2018; 87: 170–176
28. Hoffmann TK. ORATOR study: Surgery or radiotherapy for oropharyngeal carcinoma in the context of HPV? *HNO* 2020; 68: 278–279
29. Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. *Lancet Oncol* 2019; 20: 1349–1359
30. De Virgilio A, Costantino A, Mercante G, Petrucci G, Sebastiani D, Franzese C, et al. Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma. *Curr Oncol Rep* 2020; 22: 1–11
31. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. *Lancet* 2019; 393: 40–50
32. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. *Lancet* 2019; 393: 51–60
33. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 2008; 359: 1116–1127
34. Guigay J, Fayette J, Mesia R, Lafond C, Saada-Bouzid E, Geoffrois L, et al. TPEXtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). *J Clin Oncol* 2019; 37: 6002
35. Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. *Br J Cancer* 2010; 102: 1687–1691

36. Grau JJ, Caballero M, Verger E, Monzó M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. *Acta Otolaryngol* 2009; 129: 1294–1299
37. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer* 2004; 40: 2071–2076
38. Catimel G, Vermorken JB, Clavel M, De Mulder P, Judson I, Sessa C, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. *Ann Oncol* 1994; 5: 543–547
39. Meucci S, Keilholz U, Tinhofer I, Ebner OA. Mutational load and mutational patterns in relation to age in head and neck cancer. *Oncotarget* 2016; 7: 69188–69199
40. Smyth MJ, Teng MW. 2018 Nobel Prize in physiology or medicine. *Clin Transl Immunol* 2018; 7: 1041
41. Parry R V., Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi S V., et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. *Mol Cell Biol* 2005; 25: 9543–9553
42. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. *Nat Med* 2002; 8: 793–800
43. Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. *Oral Oncol* 2016; 61: 152–158
44. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet* 2018
45. Burtneess B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019; 394: 1915–1928
46. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu S V., Gilbert J, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. *J Clin Oncol* 2017; 35: 1542–1549
47. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. *Lancet Oncol* 2017; 18: 1104–1115
48. Ferris RL, Blumenschein Jr. G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2016; 375: 1856–1867
49. Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck: Results from a phase I cohort. *J Immunother Cancer* 2020; 8
50. Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, et al. Phase Ib/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. *J Clin Oncol* 2020; 38: 1154–1163
51. Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. *JAMA Oncol* 2019; 5: 67–73

Diagnostik und Therapie Myelodysplastischer Syndrome (S. 49–57)

J. Strapatsas, A. Kasprzak, R. Haas, U. Germing

1. Neukirchen J et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. *Leuk Res.* 2011; 35(12): 1591–1596
2. Kuendgen A et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification -an approach to classification of patients with t-MDS. *Leukemia.* 2020 Jun 29. doi: 10.1038/s41375-020-0917-7. Online ahead of print
3. Neukirchen J et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. *Eur J Haematol* 2009; 83(5): 477–482
4. Malcovati L et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. *Blood.* 2013; 122(17): 2943–2964
5. Geyh S et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. *Leukemia.* 2013; 27(9):1841–1851
6. Strupp C et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. *Leuk Res* 2017; 57: 78–84
7. Greenberg PL et al Revised international prognostic scoring system for myelodysplastic syndromes. *Blood.* 2012; 120(12): 2454–2465
8. Bhatia R, Deeg HJ. Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. *Curr Opin Hematol.* 2011; 18(2): 77–82
9. Schroeder T et al. Therapy-related myeloid neoplasms following treatment with radioiodine. *Haematologica* 2012; 97(2): 206–212.
10. Germing U et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. *Leuk Res* 2012; 36(6): 727–734
11. Hasserjian R et al. Myelodysplastic syndromes, overview. In. Swerdlow et al (Edt): WHO proposals for the classification of tumours of myeloid and lymphoid tissues. In press, Lyon, 2016
12. Haase D et al. New insights into the prognostic impact of the karyotype in MDS and correlation with sub types: evidence from a core dataset of 2124 patients. *Blood* 2007; 110(13): 4385–4395
13. Neukirchen J et al. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. *Cancer.* 2017; 123(23): 4608–4616
14. Buesche G, Teoman H, Wilczak W, et al: Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. *Leukemia.* 2008; 22(2): 313–322
15. Bejar R et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: Analysis of combined data sets from the International Working Group for Prognosis on MDS-molecular Committee. *Blood.* 2015; 126(23): 907
16. <https://interactive-systems.de/myelodysplastisches-syndrom-die-app-fuer-aerzte/>
17. Neukirchen J et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. *Leuk Res.* 2014; 38(1): 57–64
18. Germing U et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes. *Leukemia* 2005; 19(12): 2223–2231
19. Neumann F et al. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. *Leuk Res* 2009; 33: 232–236

20. Della Porta MG et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. *J Clin Oncol* 2009; 27(5): 754–762
21. Malcovati L et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. *J Clin Oncol* 2007; 25(23): 3503–3510
22. Silzle T et al. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. *Blood Cancer J.* 2019; 9(8): 63
23. Zipperer E et al: The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. *Haematologica.* 2014; 99(3): 31–32
24. Della Porta MG et al. Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool. *Haematologica* 2012; 97(4): 631–632
25. Rautenberg C et al. Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. *Blood Cancer J.* 2019; 9(11): 86
26. Santini V. Treatment of low-risk myelodysplastic syndromes. *Hematology Am Soc Hematol Educ Program.* 2016; 2016(1): 462–469
27. Steensma DP. Myelosplastic syndromes current treatment algorithm 2018. *Blood Cancer J.* 2018; 8(5): 47
28. Hofmann WK et al: Leitlinie Myelodysplastische Syndrome, Onkopedia, Deutsche Gesellschaft für Hämatologie und Onkologie, 2020.
<https://www.onkopedia.com/de/onkopedia/guidelines/myelodysplastische-syndrome-mds>
29. Gattermann N. Iron overload in myelodysplastic syndromes (MDS). *Int J Hematol.* 2018; 107(1): 55–63
30. Gattermann N et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. *Haematologica* 2012; 97(9): 1364–1371
31. Wermke M et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. *Lancet Haematol* 2018; 5(5): e201–e210
32. Hellström-Lindberg E et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. *Br J Haematol* 1997; 99(2): 344–351
33. Santini V et al: Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? *Blood* 2013; 122(13): 2286–2288
34. List A et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. *N Engl J Med* 2006; 355(14): 1456–1465
35. Platzbecker U et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. *Lancet Oncol.* 2017; 18(10): 1338–1347
36. Fenaux P et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *N Engl J Med.* 2020; 382(2): 140–151
37. Steensma DP et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC transfusion-dependent (TD), non-Del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimulating agent (ESA) who are lenalidomide (LEN) and HMA naive. *Blood* 2018; 132(Suppl. 1): 463
38. Giagounidis A et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. *Cancer* 2014; 120(12): 1838–4618

39. Oliva EN et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. *Lancet Haematol* 2017; 4(3): e127–e136
40. Schroeder T et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. *Biol Blood Marrow Transplant* 2019; 25(8): 1550–1559
41. Fenaux P et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol* 2009; 10(3): 223–232
42. Kuendgen A et al. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. *Oncotarget* 2018; 9(45): 27882–27894
43. DiNardo CD et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. *Am J Hematol* 2018; 93(3): 401–407
44. Schuler E et al. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy. *Ann Hematol.* 2018; 97(12): 2325–2332